Arkolith/Insider Trading/ETON/Form 4

Riedel Norbert G

DirectorEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed Jan 6, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 3, 2025Option exercise(M)25K$3.47$87K162K
Jan 3, 2025Option exercise(M)27K$3.58$98K87K
Jan 3, 2025Option exercise(M)50K$3.78$189K137K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 3, 2025Option exercise(M)27K—$00
Jan 3, 2025Option exercise(M)50K—$00
Jan 3, 2025Option exercise(M)25K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-000466) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML